Some Considerations About Cardiac Toxicity of Combination Therapy for Chronic Hepatitis C

authors:

avatar Reza Karbasi-Afshar 1 , avatar Amin Saburi 2 , 3 , *

Cardiovascular Diseases Department, Baqiyatallah University of Medical Sciences, Tehran, IR Iran
Chemical Injuries Research Center, Baqiyatallah University of Medical Sciences, Tehran, IR Iran
Baqiyatallah Research Center of Gastroenterology and Liver Diseases (BRCGL), Baqiyatallah University of Medical Sciences, Tehran, IR Iran
Hepatitis Monthly: Vol.13, issue 5; e8962
published online: May 14, 2013
article type: Letter
received: November 5, 2012
accepted: December 17, 2012
DOI: https://doi.org/10.5812/hepatmon.8962

how to cite: Karbasi-Afshar R, Saburi A. Some Considerations About Cardiac Toxicity of Combination Therapy for Chronic Hepatitis C. Hepat Mon. 2013;13(5):e8962. https://doi.org/10.5812/hepatmon.8962.

References

  • 1.

    Almawardy R, Elhammady W, Mousa N, Abotaleb S. Is combination therapy for chronic hepatitis C toxic for cardiac function? Hepat Mon. 2012;12(8). [PubMed ID: 23105944]. https://doi.org/10.5812/hepatmon.6254.

  • 2.

    Demir M, Demir C. Effect of hepatitis C virus infection on the left ventricular systolic and diastolic functions. South Med J. 2011;104(8):543-6. [PubMed ID: 21886060]. https://doi.org/10.1097/SMJ.0b013e31822462e2.

  • 3.

    Maruyama S, Koda M, Oyake N, Sato H, Fujii Y, Horie Y, et al. Myocardial injury in patients with chronic hepatitis C infection. J Hepatol. 2012. [PubMed ID: 22889957]. https://doi.org/10.1016/j.jhep.2012.07.045.

  • 4.

    Terrier B, Karras A, Cluzel P, Collet JP, Sene D, Saadoun D, et al. Presentation and Prognosis of Cardiac Involvement in Hepatitis C Virus-Related Vasculitis. Am J Cardiol. 2012. [PubMed ID: 23116612]. https://doi.org/10.1016/j.amjcard.2012.09.028.

  • 5.

    Namazee N, Sali S, Asadi S, Shafiei M, Behnava B, Alavian SM. Real Response to Therapy in Chronic Hepatitis C Virus Patients: A Study From Iran. Hepat Mon. 2012;12(9). https://doi.org/10.5812/hepatmon.6151.

  • 6.

    Perez-Alvarez R, Perez-Lopez R, Lombrana JL, Rodriguez M, Rodrigo L. Sarcoidosis in two patients with chronic hepatitis C treated with interferon, ribavirin and amantadine. J Viral Hepat. 2002;9(1):75-9. [PubMed ID: 11851906].

  • 7.

    Freiberg MS, Chang CC, Skanderson M, McGinnis K, Kuller LH, Kraemer KL, et al. The risk of incident coronary heart disease among veterans with and without HIV and hepatitis C. Circ Cardiovasc Qual Outcomes. 2011;4(4):425-32. [PubMed ID: 21712519]. https://doi.org/10.1161/CIRCOUTCOMES.110.957415.

  • 8.

    Che W, Liu W, Wei Y, Xu Y, Hou L, Matsumori A, et al. Increased serum N-terminal pro-B-type natriuretic peptide and left ventricle diastolic dysfunction in patients with hepatitis C virus infection. J Viral Hepat. 2012;19(5):327-31. [PubMed ID: 22497811]. https://doi.org/10.1111/j.1365-2893.2011.01551.x.

  • 9.

    Dabrowska MM, Mikula T, Wiercinska-Drapalo A. HCV coinfection possibly promotes left ventricular dysfunction development: analysis of brain natriuretic peptide serum levels in HCV/HIV-coinfected and HIV-monoinfected patients. Eur J Gastroenterol Hepatol. 2012;24(11):1308-12. [PubMed ID: 22825646]. https://doi.org/10.1097/MEG.0b013e32835702c6.

  • 10.

    Osztovits J, Horvath E, Tax J, Csihi L, Horvath T, Littvay L, et al. Reversible autonomic dysfunction during antiviral treatment in patients with chronic hepatitis C virus infection: Anti-HCV therapy and autonomic function. hepat Mon. 2011;11(2):114-8. [PubMed ID: 22087127].

  • 11.

    Choy-Shan A, Berezovskaya S, Zinn A, Sedlis SP, Bini EJ. Nonischemic cardiomyopathy related to pegylated interferon and ribavirin. Eur J Gastroenterol Hepatol. 2009;21(12):1438-40. [PubMed ID: 19907230]. https://doi.org/10.1097/MEG.0b013e32831cf2b3.

  • 12.

    Corey KE, Mendez-Navarro J, Barlow LL, Patwardhan V, Zheng H, Kim AY, et al. Acute hepatitis C infection lowers serum lipid levels. J Viral Hepat. 2011;18(7):e366-71. [PubMed ID: 21692949]. https://doi.org/10.1111/j.1365-2893.2011.01434.x.

  • 13.

    Taskoparan M, Serin E, Gokturk HS, Icer MO, Abaci K, Ozer B, et al. Early effect of peginterferon alpha-2b plus ribavirin treatment on blood pressure and insulin resistance in patients with chronic hepatitis C. Hepato-gastroenterol. 2011;58(107-108):875-9. [PubMed ID: 21830408].

  • 14.

    Payen JL, Pillard F, Mascarell V, Riviere D, Couzigou P, Kharlov N. Is physical activity possible and beneficial for patients with hepatitis C receiving pegylated interferon and ribavirin therapy? Gastroenterol Clin Biol. 2009;33(1 Pt 1):8-14. [PubMed ID: 19070444]. https://doi.org/10.1016/j.gcb.2008.10.009.

  • 15.

    Yan Z, Fan K, Fan Y, Wang X, Mao Q, Deng G, et al. Thyroid Dysfunction in Chinese Patients with Chronic Hepatitis C Treated with Interferon Alpha: Incidence, Long-Term Outcomes and Predictive Factors. Hepat Mon. 2012;12(9). https://doi.org/10.5812/hepatmon.6390.

  • 16.

    Boddi M, Abbate R, Chellini B, Giusti B, Giannini C, Pratesi G, et al. Hepatitis C virus RNA localization in human carotid plaques. J Clin Virol. 2010;47(1):72-5. [PubMed ID: 19896417]. https://doi.org/10.1016/j.jcv.2009.10.005.